| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
|
|
|
|||||||
|
|||||||||
LEAD ARTICLE |
From The David Geffen School of Medicine, University of California, Los Angeles, California; Cerner Health Insights, Beverly Hills, California; School of Medicine, University of Southern California, Los Angeles, California; and School of Medicine, University of Auckland, Auckland, New Zealand.
Objective: Prophylactic oophorectomy is often recommended concurrent with hysterectomy for benign disease. The optimal age for this recommendation in women at average risk for ovarian cancer has not been determined.
Methods: Using published age-specific data for absolute and relative risk, both with and without oophorectomy, for ovarian cancer, coronary heart disease, hip fracture, breast cancer, and stroke, a Markov decision analysis model was used to estimate the optimal strategy for maximizing survival for women at average risk of ovarian cancer. For each 5-year age group from 40 to 80 years, 4 strategies were compared: ovarian conservation or oophorectomy, and use of estrogen therapy or nonuse. Outcomes, as proportion of women alive at age 80 years, were measured. Sensitivity analyses were performed, varying both relative and absolute risk estimates across the range of reported values.
Results: Ovarian conservation until age 65 benefits long-term survival for women undergoing hysterectomy for benign disease. Women with oophorectomy before age 55 have 8.58% excess mortality by age 80, and those with oophorectomy before age 59 have 3.92% excess mortality. There is sustained, but decreasing, benefit until the age of 75, when excess mortality for oophorectomy is less than 1%. These results were unchanged following multiple sensitivity analyses and were most sensitive to the risk of coronary heart disease.
Conclusion: Ovarian conservation until at least age 65 benefits long-term survival for women at average risk of ovarian cancer when undergoing hysterectomy for benign disease.
This article has been cited by other articles:
|
|
 |
|
  A. Razmara, L. Sunday, C. Stirone, X. B. Wang, D. N. Krause, S. P. Duckles, and V. Procaccio Mitochondrial Effects of Estrogen Are Mediated by Estrogen Receptor {alpha} in Brain Endothelial Cells J. Pharmacol. Exp. Ther., June 1, 2008; 325(3): 782 - 790. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 T. Falcone and M. D. Walters Hysterectomy for Benign Disease Obstet. Gynecol., March 1, 2008; 111(3): 753 - 767. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 W. A. Rocca, J. H. Bower, D. M. Maraganore, J. E. Ahlskog, B. R. Grossardt, M. de Andrade, and L. J. Melton III Increased risk of parkinsonism in women who underwent oophorectomy before menopause Neurology, January 15, 2008; 70(3): 200 - 209. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
W. A. Rocca, J. H. Bower, D. M. Maraganore, J. E. Ahlskog, B. R. Grossardt, M. de Andrade, and L. J. Melton III Increased risk of cognitive impairment or dementia in women who underwent oophorectomy before menopause Neurology, September 11, 2007; 69(11): 1074 - 1083. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A Career in Pharmacology: In Search of Beauty and Joy Mol. Interv., August 1, 2007; 7(4): 183 - 189. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R. H. Fogle, F. Z. Stanczyk, X. Zhang, and R. J. Paulson Ovarian Androgen Production in Postmenopausal Women J. Clin. Endocrinol. Metab., August 1, 2007; 92(8): 3040 - 3043. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 L. Sunday, C. Osuna, D. N. Krause, and S. P. Duckles Age alters cerebrovascular inflammation and effects of estrogen Am J Physiol Heart Circ Physiol, May 1, 2007; 292(5): H2333 - H2340. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
V. Teplin, E. Vittinghoff, F. Lin, L. A. Learman, H. E. Richter, and M. Kuppermann Oophorectomy in Premenopausal Women: Health-Related Quality of Life and Sexual Functioning Obstet. Gynecol., February 1, 2007; 109(2): 347 - 354. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. P. Duckles, D. N. Krause, C. Stirone, and V. Procaccio Estrogen and mitochondria: a new paradigm for vascular protection? Mol. Interv., February 1, 2006; 6(1): 26 - 35. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
G. Smith Ovarian Conservation at the Time of Hysterectomy for Benign Disease Obstet. Gynecol., December 1, 2005; 106(6): 1413 - 1413. [Full Text] [PDF]
|
|
|
|
|
|
V. Dandolu and E. Hernandez Ovarian Conservation at the Time of Hysterectomy for Benign Disease Obstet. Gynecol., November 1, 2005; 106(5): 1106 - 1106. [Full Text] [PDF]
|
|
|
|
|
|
R. C. Wallach Ovarian Conservation at the Time of Hysterectomy for Benign Disease Obstet. Gynecol., November 1, 2005; 106(5): 1106 - 1107. [Full Text] [PDF]
|
|
|
|
 |
|
 Should Prophylactic Oophorectomy Be Performed During Hysterectomy? Journal Watch (General), September 2, 2005; 2005(902): 1 - 1. [Full Text]
|
|
|
|
|
|
D. L. Olive Dogma, Skepsis, and the Analytic Method: The Role of Prophylactic Oophorectomy at the Time of Hysterectomy Obstet. Gynecol., August 1, 2005; 106(2): 214 - 215. [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
